KalVista Pharmaceuticals (KALV) Other financing activities (2014 - 2025)
KalVista Pharmaceuticals (KALV) reported Other financing activities of $595000.0 for Q3 2025, down 80.17% on a YoY basis from $3.0 million in Q3 2024, and down 67.82% sequentially from $1.8 million in Q2 2025.
KalVista Pharmaceuticals (KALV) Other financing activities (2014 - 2025) Analysis & Trends
KalVista Pharmaceuticals (KALV) has 9 years of Other financing activities data on file, last reported at $595000.0 in Q3 2025.
- For the quarter ending Q3 2025, Other financing activities fell 80.17% year-over-year to $595000.0; the trailing twelve-month figure through Jul 2025 stood at $5.7 million (up 66.73% YoY), and the FY2025 full-year result was $5.8 million, up 794.12% from the prior year.
- Other financing activities slipped to $595000.0 in Q3 2025, from $1.8 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $3.0 million in Q3 2024 to a low of -$636000.0 in Q2 2023.
- A 5-year average of $546888.9 and a median of $244000.0 in 2023 frame the typical range for Other financing activities.
- Across the five-year window, Other financing activities surged 68600.0% in 2021 and tumbled 560.87% in 2023, its largest moves.
- Tracing KALV's Other financing activities over 5 years: stood at $63000.0 in 2021, then surged by 166.67% to $168000.0 in 2022, then retreated by 23.81% to $128000.0 in 2023, then surged by 130.47% to $295000.0 in 2024, then jumped by 101.69% to $595000.0 in 2025.
- Business Quant data shows KALV's Other financing activities at $595000.0 in Q3 2025, $1.8 million in Q2 2025, and $295000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 595,000.00 |
| Jul 31, 2025 | 595,000.00 |
| Apr 30, 2025 | 1.85 Mn |
| Apr 30, 2025 | 1.85 Mn |
| Oct 31, 2024 | 295,000.00 |
| Oct 31, 2024 | 295,000.00 |
| Jul 31, 2024 | 3.00 Mn |
| Jul 31, 2024 | 3.00 Mn |
| Apr 30, 2024 | 30,000.00 |
| Apr 30, 2024 | 30,000.00 |
| Jan 31, 2024 | 284,000.00 |
| Jan 31, 2024 | 284,000.00 |
| Oct 31, 2023 | 128,000.00 |
| Oct 31, 2023 | 128,000.00 |
| Jul 31, 2023 | 204,000.00 |
| Jul 31, 2023 | 204,000.00 |
| Apr 30, 2023 | -636,000.00 |
| Apr 30, 2023 | -636,000.00 |
| Jan 31, 2023 | 749,000.00 |
| Jan 31, 2023 | 749,000.00 |